A Registry Study of Biomarkers in Heart Valve Disease

NCT06223906 · tracked via the Priya Life Science China tracker

Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Phase

Observational

Started

2016-01-01

Last updated

2024-01-26

Condition(s) studied

Cardiovascular Diseases

Study summary

Valvular Heart Disease, impacting 2.5% of the population, is predominantly observed in the elderly and is on the rise. The primary conditions within this category are Aortic Stenosis and Mitral Regurgitation. These conditions are linked to considerable morbidity and mortality, presenting a formidable challenge in optimizing treatment strategies. Pathophysiology of Valvular Heart Disease remains poorly known. The aim of the present study is to identify biomarkers involved in this disease using multi-omics approaches

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Patients clinically diagnosed with heart valve disease in Beijing Anzhen Hospital Exclusion Criteria: * Age \< 18 years * Failure to obtain medical records and ultrasound data * Refuse follow-up

Primary outcome measure(s)

All-cause death — These data is collected during follow-up visit at 12 months after discharge
whether recidivation happened,whether other related disease happened

Trial sites (1)

Facility	City	Region	Status
Beijing Anzhen Hospital	Beijing	Beijing Municipality	Recruiting

More Beijing Institute of Heart, Lung and Blood Vessel Diseases trials in China

A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA) Recruiting

Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study Recruiting

Other trials for the same condition

The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management Recruiting

Cohort in Qianwan New District, Ningbo Recruiting

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III) Recruiting

Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases Recruiting

Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06223906 on ClinicalTrials.gov ↗ ← All trials in China